Search Results - "Jeryczynski, G"

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both by Koschmieder, S, Mughal, T I, Hasselbalch, H C, Barosi, G, Valent, P, Kiladjian, J-J, Jeryczynski, G, Gisslinger, H, Jutzi, J S, Pahl, H L, Hehlmann, R, Maria Vannucchi, A, Cervantes, F, Silver, R T, Barbui, T

“…The Philadelphia-negative myeloproliferative neoplasms (MPNs) are clonal disorders involving hematopoietic stem and progenitor cells and are associated with…”
Get full text

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study by Tefferi, A, Rumi, E, Finazzi, G, Gisslinger, H, Vannucchi, A M, Rodeghiero, F, Randi, M L, Vaidya, R, Cazzola, M, Rambaldi, A, Gisslinger, B, Pieri, L, Ruggeri, M, Bertozzi, I, Sulai, N H, Casetti, I, Carobbio, A, Jeryczynski, G, Larson, D R, Müllauer, L, Pardanani, A, Thiele, J, Passamonti, F, Barbui, T

“…Under the auspices of an International Working Group, seven centers submitted diagnostic and follow-up information on 1545 patients with World Health…”
Get full text

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria by Gisslinger, H, Jeryczynski, G, Gisslinger, B, Wölfler, A, Burgstaller, S, Buxhofer-Ausch, V, Schalling, M, Krauth, M-T, Schiefer, A-I, Kornauth, C, Simonitsch-Klupp, I, Beham-Schmid, C, Müllauer, L, Thiele, J

“…Essential thrombocythemia (ET) is currently diagnosed either by the British Committee of Standards in Haematology (BCSH) criteria that are predominantly based…”
Get full text

Response to Harrison et al. ‘Clinically relevant differences between BCSH and WHO diagnostic criteria for ET’ by Gisslinger, H, Jeryczynski, G, Wölfler, A, Beham-Schmid, C, Thiele, J

Get full text

First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience by Jeryczynski, G., Antlanger, M., Duca, F., Binder-Rodriguez, C., Reiter, T., Simonitsch-Klupp, I., Bonderman, D., Kain, R., Krauth, M.-T., Agis, H.

“…Daratumumab was the first monoclonal CD38 antibody with single-agent activity approved for the treatment of multiple myeloma. Moreover, daratumumab…”
Get full text

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria by Gisslinger, H, Jeryczynski, G, Gisslinger, B, Wölfler, A, Burgstaller, S, Buxhofer-Ausch, V, Schalling, M, Krauth, M-T, Schiefer, A-I, Kornauth, C, Simonitsch-Klupp, I, Beham-Schmid, C, Müllauer, L, Thiele, J

Get full text

Response to Harrison et al. 'Clinically relevant differences between BCSH and WHO diagnostic criteria for ET%apos by Gisslinger, H, Jeryczynski, G, Wölfler, A, Beham-Schmid, C, Thiele, J

Get full text

Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria by Gisslinger, H, Jeryczynski, G, Gisslinger, B, Wölfler, A, Burgstaller, S, Buxhofer-Ausch, V, Schalling, M, Krauth, M-T, Schiefer, A-I, Kornauth, C, Simonitsch-Klupp, I, Beham-Schmid, C, Müllauer, L, Thiele, J

“…Correction to: Leukemia (2016) 30, 1126–1132; doi:10.1038/leu.2015.360 Following the publication of this Article, the authors noted that there were errors in…”
Get full text